Terray Therapeutics is a startup that operates in the pharmaceutical industry, focusing on the discovery and development of small molecule drugs. The company uses a unique blend of experimentation and computation, leveraging high-quality data at scale to unlock the potential of generative AI for small molecule discovery. This innovative approach allows Terray to address some of the most challenging therapeutic problems.

The company's business model is centered around a workflow that equally emphasizes wet lab science and AI. This approach enables Terray to generate a vast experimental dataset, which includes more than two billion unique target-ligand binding measurements, with 150 million new measurements added every month. This wealth of data allows for accurate molecular property prediction using deep learning regression models.

Terray's rapid design-make-test-analyze cycle, which takes less than a month per target, allows the company to explore chemical space efficiently, experimentally measuring millions of molecules at a time. This process enables the company to quickly identify potent, selective small molecules for many targets simultaneously, providing multiple points of intervention to treat diseases.

The company's primary focus is on immunology, but it also partners with large pharmaceutical and biotech companies to apply its platform to a wide range of challenging targets and therapeutic areas. This partnership model provides an additional revenue stream for the company, alongside its internal drug discovery efforts.

Keywords: Small Molecule Drugs, Drug Discovery, Generative AI, Wet Lab Science, High-Quality Data, Deep Learning Regression Models, Rapid Design-Make-Test-Analyze Cycle, Immunology, Pharmaceutical Partnerships, Therapeutic Challenges.